VRNG Alerts 08/16/2014 04:27:18 $VRNG How did they FUND

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
VRNG Alerts 08/16/2014 04:27:18 $VRNG
How did they FUND all those Patent purchases?
$31,700,000-$30,496,155=A GREAT DEAL LESS CASH!
Don't forget the $30,496,155 REFUND BACK TO GOOGLE!
I don't need a calculator to add 0 + 0!
How much did they pay for the big patent portfolio they bought? So they have 39 cents per share in cash, that patent portfolio they bought off of,..Nokia? The value as a big board entity. The longshot value of Google appeals etc. Whatever value you give for other lawsuits based off the now tainted patents. What do you get $1.25-$1.50 per share worth of meat left on the bones?
Losers thats what you get for investing in a company slows technological progress because your litigation nonsense
There was a report of $31.7 million in cash at the end of June. And an additional $2.3 million deposited with various international courts for injunction enforcement.

Common shares outstanding is approx 87.2 million. There are approx 115 million shares on a fully diluted basis. But because 17.4 million of them are related to warrants (at $1.76 and $5.06) it probably doesn't make sense to count them when we have a market closing price per share of $0.88.

There are 12 million more shares related to the employee incentive plan.

So using the most favorable metrics, I believe it would be approximately $0.39 cash per share. But I don't know the cash burn the last two and half months. I am sure it is more than zero.
Get a better calculator.
One other point, the patents in question were directly related to proprietary query based content ad retrieval, which is Google Adsense. In essence, this voids ANY claim Vringo has to use or revenue generated from its use. In other words, Vringo is UP THE CREEK & will not obtain ANY revenue tied to those patents. No matter how the advocates for VRINGO twist this on the wire & on the message boards, LOSS of this revenue stream is MAJOR for a company this size!
How much cash per share does vringo have left?
Nice add...
Unforunately, with the Earnings loss & the revenue impacting patent losses, VRNG is going to correct & fall inline with it's true support level, in the low .50's. This stock is in a dead cat bounce & the only thing that will send it back up is a positive Earnings Report. The short rally wont happen until this bounce bottoms out. Short sellers are going to squeeze every ounce of gain out of VRNG, and, they will not leave 1/2 of a dollar sitting on the table.
Sort of yes but not that simple.ken lang is the inventor of the patents in question was involved as well
EPS is -.49. Something doesnt add up.
Reversing Trial Court For error
Would some trial lawyer respond to this? I've been out of law school for over 50 years and had little trial experience. I recall however that appellate courts have to give juriy opinions great deference and where an agency has opined as the Patent office here has more than once, that the courts have to give that even greater weight. So now we have the CAFC knowing more about patent law than the patent office?? If the above is correct, IMO en banc is clearly warranted here and it will reverse the appellate court. Less
Sentiment: Hold
vringo bought some old patents and they thought they were gonna make billions suing ?
So did we still win some money as before but lost the later part? Or did it all just go to shit? After being here for years this is bs.
Unfortunately this is the down fall of USA. I don't really care I'm a cunuck, and at a moments notice I will be out of this messed up us, sadly. gl.
I think it's now illegal to say "God Bless" yes words we used to form our nation!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 0

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 141

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Hyundai’s Third SUV Crown Matters Beyond the Trophy

Updated Category News Views 0

A Three-Year Streak Is Not Just Decorative Three straight SUV-brand wins can make even a cynical car watcher pause. Hyundai has been named U.S. News & World Report’s 2027 Best SUV Brand after editors assessed vehicles from 39 brands, and that is a useful bit of outside validation in a segment where nearly everybody is throwing sheet metal, screens, and marketing dollars...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 79

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 131

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 151

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 30

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 90

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 24

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading

Top 5 Most Recently Viewed Articles

DallasNews Shareholders Urged to Support Merger Deal with Hearst

Updated Category News Views 101

Overview of the DallasNews and Hearst Merger DallasNews Corporation, the parent company of The Dallas Morning News, has proposed a significant merger with Hearst, a prominent media organization. This merger offers an enticing cash value of $15.00 per share, bringing impressive benefits to shareholders. Recently, Glass Lewis, an independent proxy advisory firm, recommended...

Continue Reading
GitLab Director Karen Blasing's Recent Stock Transactions Explained

Updated Category News Views 154

Analyzing the Recent Insider Trading at GitLab GitLab Inc. (NASDAQ:GTLB) has recently drawn the attention of investors and market analysts due to stock transactions made by its director, Karen Blasing. A recent filing with the U.S. Securities and Exchange Commission revealed that Blasing sold a considerable amount of her stock holdings, totaling more than $173,000....

Continue Reading
Avenue Living's Strategic $350 Million Debenture Offering

Updated Category News Views 202

Avenue Living Announces $350 Million Senior Unsecured Debenture Offering Avenue Living (2014) LP has recently announced a significant financial move with a $350 million offering of Series B senior unsecured debentures. This opportunity is set to be priced at par and is due by September 25, 2028, indicating a long-term strategy for the company’s financing needs. Details...

Continue Reading
Fagron Reports Strong Financial Growth with Strategic Outlook

Updated Category News Views 349

Fagron's Remarkable Financial Performance Fagron, a global leader in pharmaceutical compounding, recently showcased its impressive results for the period ending December 31, 2024. The company’s financial achievements highlight significant growth across various sectors and regions in the pharmaceutical industry, reinforcing its commitment to excellence and innovation....

Continue Reading
Dizal's Sunvozertinib Receives Breakthrough Therapy Designation

Updated Category News Views 444

Dizal's Sunvozertinib Achieves Breakthrough Therapy Designation Dizal, a biopharmaceutical company dedicated to developing innovative cancer and immunological therapies, recently announced an important milestone. The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for sunvozertinib, aimed at...

Continue Reading